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Abstract
Background:  The presynaptic protein α -synuclein is involved in a range of neurodegenerative
diseases. Here we analyze potential compensatory mechanisms in α -synuclein null mutant mice.
Furthermore, the findings reveal problems that may be associated with inbred mouse strains.
Results:  Expression profiling by cDNA array technology in a transgenic mouse model revealed
striking differences only in the expression level of α -synuclein. This was caused by a chromosomal
deletion of the α -synuclein locus in the C57BL/6J inbred strain used for backcrossing. However,
the deletion is only present in a subpopulation of C57BL/6J mice, namely animals from Harlan. No
other genes are known to be affected by the deletion, which is estimated to be smaller than 2 cM.
We propose to name this strain C57BL/6S. C57BL/6S animals appear phenotypically normal. They
show no upregulation of β -synuclein or γ -synuclein, excluding a compensatory mechanism. Also,
the expression of synphilin-1 was unaffected.
Conclusions:  The C57BL/6S strain should help in the understanding of the physiological function
of α -synuclein and its involvement in synucleinopathies. Also, the findings exemplify unexpected
complications that may arise during the study of transgenic models or inbred strains, in particular
when combined with genome wide screening techniques.
Background
The linkage of two missense mutations in the human α -
synuclein gene to rare inherited forms of Parkinson's dis-
ease (PD) [1,2] has implied that the protein plays a part
in neurodegenerative diseases. Subsequently, α -synu-
clein was shown to be the major component of Lewy bod-
ies (LB) in PD [3,4] as well as in a range of other neuro-
degenerative diseases, classified as synucleinopathies
[for review see [5]].
During development, mice express increasing levels of α -
synuclein mRNA, peaking at postnatal day seven (P7)
[6,7]. The α -synuclein protein is mainly expressed in
neurons and located in the presynaptic termini [8,9]. So
far, a number of animal models have been developed for
the study of α -synuclein. Overexpression of wildtype or
mutant α -synucleins in mice [10,11] or Drosophila[12]
resulted in pathological and behavioral phenotypes simi-
lar to those found in PD. Homozygous α -synuclein
knockout mice are viable, fertile, and have apparently
normal brain morphology. Hippocampal synaptic plas-
ticity in these mice was identical to wildtype animals as
judged by LTP measurements. However, an alteration of
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dopamine release in the nigrostriatal system was ob-
served [13].
The primary protein sequence of β -synuclein [14,15]
shows a high degree of identity to α -synuclein (particu-
larly in the N-terminal region), with both sharing similar
expression patterns and subcellular localization [15,16].
Thus, it can be speculated that the two proteins may have
similar physiological functions. γ -synuclein [17], the
third member of the synuclein family is mainly expressed
in the peripheral nervous system throughout develop-
ment and, at lower levels, in brain [18]. β - and γ -synucle-
in have also been implicated in axonal pathological
processes [19].
Yeast-two-hybrid analysis with human DNA fragments
has identified synphilin-1 as a specific interaction part-
ner of α -synuclein [20]. Little is known about its func-
tion, however, it was shown to be present in most Lewy
bodies in PD (but absent from α -synuclein positive Lewy
neurites) [21].
Wide scale mRNA expression profiling by cDNA array
technology on a transgenic mouse model led us to the
discovery of a C57BL/6J substrain with a chromosomal
deletion spanning the α -synuclein gene locus (Snca).
Subsequently, we analyzed the consequences of the ab-
sence of α -synuclein on the expression levels of β - and γ -
synuclein and synphilin-1.
Results
The analysis of brain mRNA expression profiles by cDNA
array technology demonstrated striking differences in
the expression levels of α -synuclein in an engineered
mouse model (Kneussel, Annala, Schoepfer; in prepara-
tion), with arbitrary expression units of 3495 (wildtype)
and 457 (transgenic). All other analyzed genes were not
significantly altered in their expression (less than factor
2x; Fig. 1A). The transgenic animals used in this study
had been backcrossed into the BL6JHUK strain (see
methods). Since further investigation on the transgenic
model led to contradictory results (data not shown),
mRNA expression levels were compared between differ-
ent wildtype strains used in the generation of the trans-
genic mice.
α -synuclein is not expressed in the BL6JHUK strain at any 
developmental stage
Expression of α -synuclein in brains of 129/Ola, ICR, and
BL6JHUK mice was compared by Northern blot analy-
sis. A clear difference between the strains was observed
at any considered developmental time point. No signal
could be detected in BL6JHUK mice, whereas the other
strains expressed equal amounts of the α -synuclein tran-
script (Fig. 1B). Between P0 and P15 mRNA expression
increased in 129/Ola and ICR mice as previously de-
scribed [6,7]. Expression of α -synuclein mRNA was ob-
served as early as on embryonic day 14 (E14; on total
embryo RNA) and E17 (brain RNA) in ICR but not in
BL6JHUK mice (data not shown).
Consistent with this result, no detectable expression of
α -synuclein protein was observed in BL6JHUK in con-
trast to the 129/Ola and ICR strains (Fig. 1C). In agree-
ment with previous studies protein levels increased
during postnatal development [7], but were consistently
absent from the BL6JHUK strain. At prenatal stages (us-
ing homogenates from embryo at E14 and brain at E17),
α -synuclein expression was below detection levels in ICR
and BL6JHUK animals (data not shown).
The BL6JHUK strain is a knockout model for α -synuclein
Although α -synuclein expression was not observed in the
BL6JHUK strain the detection of low expression levels
could require methods of greater sensitivity. Therefore,
mRNA expression of α -synuclein was determined by
semi-quantitative RT-PCR analysis (Fig. 2A). Amplifica-
tion on brain total RNA of an ICR mouse at P15 with spe-
cific α -synuclein primers resulted in a detectable cDNA
fragment after as few as 20 PCR cycles. However no
product was detected using BL6JHUK RNA, even after
35 cycles of amplification. When BL6JHUK RNA was
contaminated with low levels of ICR RNA the appear-
ance of the α -synuclein PCR product could be observed
even at a dilution factor of 104 after 35 cycles. This indi-
cates that expression of α -synuclein mRNA in BL6JHUK
is decreased by at least this factor compared to the ICR
strain. Identical results were obtained with P8 and E14
samples (data not shown). Therefore, the α -synuclein
gene locus (Snca) in the BL6JHUK strain must be con-
sidered a null allele.
To further elucidate the mechanism underlying this phe-
nomenon, the presence of the Snca locus was analyzed.
Genomic PCR experiments revealed the absence of the
α -synuclein locus in BL6JHUK mice (Fig. 2B). In con-
trast to the ICR and 129/Ola strains, amplification of ge-
nomic DNA fragments corresponding to exon 4 and exon
6 of the α -synuclein gene yielded no PCR product in the
BL6JHUK sample. PCR amplification spanning intronic
α -synuclein sequences (exons 1 to 2, exons 5 to 6) yielded
identical results (data not shown). Reproducibility was
confirmed on a number of BL6JHUK mice (n = 8) from
four batches of animals. Sequence alignment with the
mouse  α -synuclein chromosomal sequence (GenBank
AF163865; [22]) locates the chromosome 6 genomic
marker D6Mit357 to the sequence between exons 4 and
5 (data not shown). Again, this primer pair did not yield
an amplification product on BL6JHUK DNA, whereas
loci in close proximity to Snca were not deleted (Fig. 2C).BMC Neuroscience 2001, 2:11 http://www.biomedcentral.com/1471-2202/2/11
Figure 1
α -synuclein expression levels. A. cDNA array experiment using brain polyA+-RNA from a transgenic mouse and a
wildtype littermate at the developmental time point E18.5. From all analyzed genes (approximately 9000 ESTs), only the
expression of α -synuclein (GenBank W41663) was significantly altered (indicated by an arrow; differential expression factor
7.6x). The data are represented without background substraction. Expression is quantified as units of fluorescence intensity.
Diagonals indicate differential expression by 2x and 10x, respectively.B. Northern blot of brain polyA+-RNA (500 ng per lane)
from 129/Ola, ICR, and BL6JHUK mice at the developmental time points P0, P8, P15, and adult, probed with an α -synuclein
3'UTR probe. The α -synuclein transcript size is approximately 1.5 kB. RNA samples were pooled from 4 animals (at P0), or
from 2 animals (at P8 and P15) from the same litter. After stripping the membrane was re-probed with an actin probe. C. Brain
homogenate from 129/Ola, ICR, and BL6JHUK mice at P0, P8, P15, and adult age was separated by 15% SDS-PAGE (20 µg pro-
tein per lane). The Western blot membrane was simultaneously probed with the monoclonal anti α -synuclein and anti α -tubu-
lin antibodies. Recognized protein bands have apparent molecular weights of approximately 19 kDa and 55 kDa, respectively. BMC Neuroscience 2001, 2:11 http://www.biomedcentral.com/1471-2202/2/11
Figure 2
Deletion of the α -synuclein gene locus in the BL6JHUK strain. A. Semi-quantitative analysis of α -synuclein expression
in BL6JHUK mice by RT-PCR, sized on a 1.5% agarose gel. A 568 bp α -synuclein band is detected after as few as 20 PCR cycles
on brain total RNA of an ICR mouse at P15. No signal was detected in the BL6JHUK sample even after 35 cycles. However,
when the BL6JHUK sample was contaminated with as little as 0.01% ICR RNA, the α -synuclein band could still be detected
after 35 PCR cycles. The control shows amplification of a 473 bp tubulin fragment with constant 35 cycles. B. Probing for the
presence of the α -synuclein gene in the ICR, 129/Ola, BL6JHUK, BL6N, BL6, and BL6Jax strains. Genomic α -synuclein DNA
fragments of exon 4 and of exon 6 were amplified by PCR and the products separated on a 2% agarose gel. In a control exper-
iment, a fragment of the NR1 gene was amplified. Fragment sizes are 130 bp, 266 bp, and 508 bp, respectively. C. Genomic
PCR on BL6JHUK and BL6Jax DNA with the markers Atoh2, D6Mit122, D6Mit357, Atoh1, and D6Mit299. The D6Mit357 signal
was absent from the BL6JHUK strain, whereas all other markers amplified on the two DNA samples. Atoh2 and D6Mit122 are
both currently mapped to about 1 cM upstream of Snca (marker D6Mit357), Atoh1 and D6Mit299 both to about 1 cM down-
stream of this locus [[22]; and databases cited there]. PCR products were separated on a 2% agarose gel.BMC Neuroscience 2001, 2:11 http://www.biomedcentral.com/1471-2202/2/11
Further analysis of mouse strains related to BL6JHUK
(BL6N and BL6) revealed that both did not contain the
deletion (Fig. 2B). Western blotting confirmed α -synu-
clein protein expression in adult BL6N and BL6 animals
(data not shown). To establish whether the entire
C57BL/6J strain was affected by the deletion, C57BL/6J
DNA samples from two different sources were com-
pared. It appeared that BL6Jax DNA (C57BL/6J provid-
ed by Jackson Laboratory, Bar Harbor, ME) was not
affected by the deletion. This is in contrast to BL6JHUK
DNA (C57BL/6J from Harlan, Bicester, UK) (Figs. 2B
and 2C). Therefore only a subpopulation of the C57BL/
6J mice carries the deletion of the Snca locus and thus we
suggest that this new strain should be called 'C57BL/6S'.
Lack of Compensatory upregulation of β  or γ  -synuclein in 
α -synuclein null mice BL6JHUK
Since α -synuclein null mice do not display any striking
phenotype (our observation; [13]) expression of β -synu-
clein was analyzed for possible compensatory mecha-
nisms. Western blot analysis revealed that protein levels
of β -synuclein remain unaffected by the α -synuclein de-
letion at any stage of postnatal development (Fig. 3A).
Expression of the 19 kDa protein was uniform in the 129/
Ola, ICR, and the BL6JHUK strain and increased notice-
ably during postnatal development.
Furthermore, Northern blot analysis indicated that the
expression of γ -synuclein was not significantly altered by
the absence of α -synuclein in BL6JHUK mice during
postnatal development (Fig. 3B). This had been already
indicated by the array analysis (Fig. 1A). The γ -synuclein
signal (arbitrary expression units) was 2325 (wildtype)
vs. 2492 (transgenic animal with Snca deletion).
Lack of alteration of synphilin-1 expression in α -synuclein 
null mice BL6JHUK
Human α -synuclein had been shown to specifically inter-
act with human synphilin-1 protein [20]. Therefore, the
influence of the α -synuclein deletion on expression lev-
els of synphilin-1 in mice was tested. Synphilin-1 expres-
sion was found to be unaffected by the absence of α -
synuclein in the knockout strain BL6JHUK. Equal levels
of synphilin-1 transcript were detected in the 129/Ola,
ICR, and BL6JHUK strains by Northern blotting (Fig.
4A). Likewise, protein expression levels were unaltered
between the strains, as judged by Western blot analysis,
and showed a slight increase during postnatal develop-
ment (Fig. 4B).
Discussion
The results unequivocally show that a subpopulation of
C57BL/6J mice carry a chromosomal deletion of the α -
synuclein gene locus (Snca). This deletion is responsible
for the absence of α -synuclein mRNA and protein ex-
pression in affected animals. Within this paper, the sub-
strain has been referred to as BL6JHUK according to its
source (see methods). We now propose to name this new
strain C57BL/6S (S for α -synuclein).
The discovery of a chromosomal deletion of α -synuclein
in C57BL/6J DNA was unexpected since, for example,
the protein had been previously detected in brain from
wildtype C57BL/6 mice [16]. Furthermore, α -synuclein
cDNA clones have been isolated from C57BL/6J libraries
(GenBank W41663 and AA266446), implying the pres-
ence of the α -synuclein gene. Indeed, the deletion of α -
synuclein was shown to only affect a subpopulation of
C57BL/6J animals and did not occur in the related
strains C57BL/6N and C57BL/6. It remains to be estab-
Figure 3
Developmental expression of β - and γ -synuclein in dif-
ferent mouse strains. A. 15% SDS-PAGE was performed
on brain homogenate from the 129/Ola, ICR, and the
BL6JHUK strain at time points P0, P8, P15, and adult (20 µg
protein per lane). The Western blot membrane was probed
with polyclonal anti β -synuclein IgG, detecting the 19 kDa
protein. The lower part shows the anti α -tubulin control. B.
Northern blot of brain polyA+-RNA (500 ng per lane) from
129/Ola, ICR, and BL6JHUK mice at different developmental
stages (P0, P8, P15, and adult). Probing with a 3'UTR γ -synu-
clein probe detects a transcript of approximately 0.8 kB.
RNA samples were pooled from 4 animals (at P0), or from 2
animals (at P8 and P15) from one litter (same membrane as
in Fig. 1B, actin control identical to Fig. 1B). BMC Neuroscience 2001, 2:11 http://www.biomedcentral.com/1471-2202/2/11
lished how widespread this deletion is within different
C57BL/6J colonies. The deletion was not present in the
C57BL/6J DNA provided by the Jackson Laboratory
(Bar Harbor, ME), in contrast to C57BL/6J from Harlan
(Bicester, UK). All animals from this source that were an-
alyzed during the year 2000 were shown to carry the mu-
tation (n = 8 from four batches of animals), suggesting
that a majority of the colony is affected. However, it can-
not be excluded, that the colony is heterogeneous for the
deletion. From the information available to us, it seems
likely that the mutation has been present in the colony as
early as 1998. Further investigation will be needed to de-
termine the prevalence of the deletion within the mouse
colony and the time point at which it occurred.
The chromosomal deletion was shown to cover the com-
plete Snca locus. Exon 1 and exon 6 of the gene are 97 kB
apart (GenBank AF163865; mouse strain 129/SvJ; [22])
and flank the chromosome 6 marker D6Mit357. Howev-
er, the deletion was shown not to include loci currently
mapped at a distance of only 1 cM to each side of Snca,
namely Atoh1 and Atoh2[22]. At present, no other genes
are known to be located between Atoh1 and Atoh2.
In the future, large scale screening of expression profiles
[for example [23]] by cDNA array technology or pro-
teomics is likely to identify unexpected genomic variants.
It will be interesting to see how frequently such deletions
occur and whether they play an important role in evolu-
tion. For the moment, the occurrence of such deletions
has implications on the number of genetic markers need-
ed to validate mouse strains.
C57BL/6S mice are fertile, appear to be healthy, and
have normal life expectancies, in agreement with the
data on α -synuclein knockout mice [13]. To explain the
lack of a noticeable phenotype in the absence of α -synu-
clein, potential compensatory mechanisms were tested.
However, there was no indication of altered β - or γ -synu-
clein expression in the C57BL/6S strain. Likewise, the
absence of α -synuclein did not alter expression levels of
synphilin-1, with which it interacts specifically [20]. De-
spite the absence of compensatory upregulation it is still
possible that α - and β -synuclein have similar functions
and this would be addressed by deleting both loci. Fur-
thermore, it can be inferred from the initial cDNA array
experiment that the deletion of Snca does not result in
significant changes in the expression levels of the other
genes represented on the array (Fig. 1A). These include
ubiquitin C-terminal hydrolase L1 that also has been
found in LB [24]. This transcript was highly expressed
with 16699 (wildtype) vs. 14393 (transgenic animal with
Snca deletion) arbitrary expression units.
Conclusions
We have discovered a chromosomal deletion in a sub-
population of the widely used inbred mouse strain
C57BL/6J. Such cryptic genetic alterations in a model
thought to be well defined may underlie confusing re-
sults of well executed experiments. The described strain
C57BL/6S has a deletion of the α -synuclein locus and
may be a valuable tool to obtain a better insight into the
physiological function of α -synuclein and its role in sy-
nucleinopathies.
Figure 4
Developmental expression of synphilin-1 in different
mouse strains.  A. Northern blot of brain polyA+-RNA
(500 ng per lane) from 129/Ola, ICR, and BL6JHUK mice at
different developmental stages (P0, P8, P15, and adult). Prob-
ing with a 1.5 kB synphilin-1 probe detects a transcript of
approximately 4 kB. RNA samples were pooled from 4 ani-
mals (at P0), or from 2 animals (at P8 and P15) from one lit-
ter. After stripping, the membrane was re-probed with an
actin probe. B. Brain homogenate from 129/Ola, ICR, and
BL6JHUK mice at P0, P8, P15, and adult age separated by
7.5% SDS-PAGE (30 µg protein per lane). The Western blot
membrane was sequentially probed with polyclonal anti syn-
philin-1 and monoclonal anti α -tubulin antibodies. The recog-
nized proteins have apparent molecular weights of
approximately 85 kDa and 55 kDa, respectively.BMC Neuroscience 2001, 2:11 http://www.biomedcentral.com/1471-2202/2/11
Materials and Methods
Mouse strains and genomic DNA
C57BL/6J mice were obtained from Harlan (Bicester,
UK; C57BL/6JOlaHsd). Mice from this source are re-
ferred to as BL6JHUK within this publication.
C57BL/6 mice (Harlan, Bicester, UK) are referred to as
BL6, and C57BL/6N (Charles River, Margate, UK) as
BL6N.
Furthermore, C57BL/6J genomic DNA was obtained
from Jackson Laboratory (Bar Harbor, ME; stock
JR0664, preparation P34170) and is referred to as
BL6Jax.
ICR and 129/Ola mice were obtained from Harlan
(Bicester, UK).
Tissue from adult animals (generally three months old)
was isolated from mice obtained through their respective
suppliers. Samples at developmental stages up to three
weeks originate from animals bred at UCL for less than
two generations. Unless otherwise stated, material used
in the experiments was obtained from individual ani-
mals. Generally, male animals were used.
RNA analysis
Total RNA was isolated from brains (including cerebel-
lum) using Trizol reagent (Gibco, Life Technologies,
Paisley, UK). PolyA+-RNA was prepared with oligo-dT
columns (Oligotex; Qiagen, Crawley, UK). The array ex-
periment was performed by Genome Systems (now In-
cyte Genomics, St. Louis, MO; mouse GEM 1 microarray,
cat. No. GEM-5200) on 600 ng polyA+-RNA (for further
information see  [http://www.incyte.com/gem] ). For
Northern blot analysis RNA was size separated by for-
maldehyde denaturing gel electrophoresis and trans-
ferred onto Hybond-N membranes (Amersham
Pharmacia, Little Chalfont, UK). After hybridization of
the random-primed 32P-probes (Prime-It-Kit; Strata-
gene, Amsterdam, Holland) the final stringency washes
were 0.3x SSPE at 65°C.
Restriction fragments of an α -synuclein cDNA clone
(GenBank W41663; I.M.A.G.E. Consortium CloneID
353366; HGMP, Cambridge, UK;  [http://im-
age.llnl.gov] ; [25]) were used to generate radiolabelled
probes. A probe to the 3'-untranslated region (3'UTR) of
α -synuclein was obtained from a 557 bp fragment (BglII/
NotI). The 201 bp EcoRI/NcoI (5'UTR) and 469 bp
NcoI/NcoI fragments (coding sequence) led to identical
results (data not shown).
A 3'UTR probe of γ -synuclein was obtained from a 394
bp restriction fragment (EcoRI/NotI) of a cDNA clone
(GenBank BE133521; I.M.A.G.E. Consortium CloneID
1533487; HGMP, Cambridge, UK;  [http://im-
age.llnl.gov] ; [25]). Consistent results were obtained us-
ing probes for the coding sequence or for full-length
cDNA (data not shown).
A probe to the synphilin-1 coding sequence was generat-
ed using a 1.5 kB RT-PCR fragment (primers CTTCTGT
GGCTTCTTCAGTTTATGC and GCTGCCTTATTCTTTC
CTTTGCTAGC). Same results were obtained with a
slightly overlapping 290 bp synphilin-1 fragment (prim-
ers CAGTTGGAGTGCGTACGCTGGATGGT and
GGCTTTTCCCCAGCGTGGTTCTGCAT; data not
shown). Primers were designed using the human synphi-
lin-1 sequence (GenBank AF076929). Sequencing re-
vealed a high degree of identity between the human and
mouse sequences (approximately 90% and 85% identity
within two stretches of about 500 bp each on the cDNA
level; data not shown).
A murine 0.9 kB probe to the actin coding sequence
served as positive control, revealing a band of about 2.2
kB in brain RNA.
Westerns blot analysis
Total brain tissue was homogenized in boiling lysis buff-
er (1% SDS, 1 mM Na3VO4, 10 mM Tris, pH 7.4), micro-
waved for 15 seconds, and cleared by centrifugation.
Samples were denatured in loading buffer containing
SDS and β -mercaptoethanol, followed by SDS-PAGE, us-
ing prestained protein markers (Biorad, Hemel Hemp-
stead, UK). Proteins were blotted onto Hybond-P
membranes (Amersham Pharmacia).
Membranes were blocked in buffer containing 50 mM
Tris pH 8.0, 2 mM CaCl2, 80 mM NaCl, 0.2% (v/v) Igepal
CA-630 (Sigma, Poole, UK) and 5% (w/v) dried skimmed
milk (Marvel; Premier Brands, Wirral, UK) for one hour
to overnight. Primary antibodies were applied for one
hour, followed by washes with blocking buffer. Peroxi-
dase-conjugated secondary antibodies (goat anti-rabbit
or goat anti-mouse IgG; 111-035-003 and 115-035-003;
Jackson ImmunoResearch Laboratories, West Grove,
PA) were incubated for one hour at a dilution of 1:10000,
followed by washes in blocking buffer and PBS. Mem-
branes were developed with ECL Plus reagent (Amer-
sham Pharmacia) and exposed on film (X-OMAT-AR;
Kodak, Hemel Hempstead, UK). Membranes were
stripped and re-probed according to the manufacturer's
protocol.
Monoclonal mouse anti rat α -synuclein IgG1 (S63320;
Transduction Laboratories, Lexington, KY) was used at a
concentration of 1:500. Polyclonal rabbit anti human β -
synuclein IgG (1:2500; SA3405; Affiniti, Mamhead, UK)BMC Neuroscience 2001, 2:11 http://www.biomedcentral.com/1471-2202/2/11
and polyclonal rabbit anti human synphilin-1 IgG
(1:1000; ab6179; Abcam, Cambridge, UK) were both
used in alternative blocking buffer (PBS containing
0.05% Tween20 and 3% BSA). The synphilin-1 antibody
was raised against an N-terminal epitope and recognized
several protein bands on Western blots. Since only one of
these proteins was of the expected size (approximately
85 kDa) and expressed throughout development this was
taken for the genuine target protein synphilin-1.
Monoclonal mouse anti chick α -tubulin IgG1 (1:20000;
T9026; Sigma) detected a 55 kDa band, which was used
as positive control.
Genomic PCR
Genomic DNA was isolated from tail samples using a
proteinase K / SDS protocol [26] with the exception of
BL6Jax DNA (C57BL/6J, stock JR0664, preparation
P34170; Jackson Laboratory, Bar Harbor, ME).
Touchdown PCR on 1 µg genomic DNA in 25 µl included
denaturation at 94°C (30 sec), annealing at 68°C (30 sec
with dT = -0.5°C each cycle), and extension at 72°C (45
sec) for 30 cycles, followed by further 10 cycles with con-
stant 52°C annealing temperature. Specific primers am-
plified mouse α -synuclein exon 4
(AGAAGACCAAAGAGCAAGTGACA and ATCTGGTC
CTTCTTGACAAAGC, 130 bp fragment) and α -synuclein
exon 6 (AAGACTATGAGCCTGAAGCCTAAG and AGT
GTGAAGCCACAACAATATCC, 266 bp), as well as
NMDA receptor subunit NR1 (exons 18 to 19, GTCCAT
ACTCAAGTGAGTCTGCCC and CAGGGGCATTGCT
GCGGGAGTC, 508 bp) as a positive control. This was al-
ternatively performed as an internal control (data not
shown).
Amplification of the chromosome 6 genomic marker
D6Mit357 (UniSTS database, NCBI,  [http://www.nc-
bi.nlm.nih.gov/genome/sts] ) yielded a 100 bp product
(primers TACAATGGCTCTCCTCCCTG and CCTCAG
GATTTAAATAAATTCAAGC). The size of the deletion
was estimated using a range of genetic markers close to
the Snca locus. Results shown here include the following
markers: mouse atonal protein homolog 1 and 2 (Atoh1,
also known as MATH-1, GenBank D43694; primers CT
GCAGGCGAGAGACCTTC and TCAGCTTGCACAGCT
GTTC, 271 bp product; Atoh2, also known as Nex-1, Gen-
Bank U29086, TACTGCAGTGCATATGAATC and TCG
TAAGGGAAGTGGCTGTC, 245 bp), and the markers
D6Mit122 (GACACCCAGCATCCATCTTT and TTG
TAATTTTTAAAAGATAGGTGTGTG, 139 bp) and
D6Mit299 (TCATGAATATCAAAGACACACATCC and
AAGCACATGCATTAGTATTTCCC, 119 bp). In these ex-
periments genomic DNA was subjected to 30 PCR cycles
(94°C/30 sec, 55°C/30 sec and 72°C/30 sec). Products
were sized with MspI digested pBluescript II KS(+)
(Stratagene).
RT-PCR
The reverse transcriptase reaction was performed on 50
ng total RNA in 25 µl containing 0.25 µg oligo-dT primer
with Ready-To-Go RT-PCR beads (Amersham Pharma-
cia) at 42°C for 30 minutes, followed by PCR cycling
(94°C/30 sec, 55°C/30 sec, 72°C/45 sec) with 5 pmol of
each specific primer. The primers AACTGCAGTTCT
TCAGAAGCCTAGGGAGC and GCTCTAGACTGGGCA
CATTGGAACTGAG were used to amplify a 568 bp
mouse α -synuclein fragment (exons 1 to 6 on cDNA).
Amplification of a 473 bp mouse tubulin α 1 (Tuba1) frag-
ment (ACACCTTCTTCAGTGAGACAGG and CTCATT
GTCTACCATGAAGGCAC) served as a positive control.
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